## **CANCER RESEARCH UK & UCL CANCER TRIALS CENTRE**

## IMP Label RA submission form

Trial name:	UKALL14
Protocol version and date	Version 3 18 Aug 2010
Sponsor ID	UCL/08/0167
EudraCT	2009-012717-22
Chief Investigator	Dr Adele Fielding
IMP	Nelarabine
Label version and date:	Version 2 21Oct10

For Clinical Trial Use ONLY		
UKALL14		
EudraCT no: 2009-012717-22		
Sponsor: University College London - UCL/08/0167		
Cancer Research UK & UCL Cancer Trials Centre		
Site name/address:		
Principal Investigator:		
Storage conditions: Refer to SPC		
Directions for use: Refer to Protocol		

**Legend**: Site name/address and Principal Investigator are blank and are to be added by the site.

Comments: Nelarabine will be delivered as commercial stock.

Pharmacy must add the above label upon receipt to designate its use in a clinical trial.

All other information required by Annex 13 will be on the trade packs.

The format provided for the label will be at a size legible for its intended use.

Sponsor Approval	
Name:	F.CICPEU
Job Title:	CLIMENC TRIAL PHARTISCIST
Signature:	
Date:	21 Oct 2010